Descrizione del progetto
Nuovi vaccini e strumenti diagnostici per migliorare la salute e la produttività degli animali
Le malattie riproduttive infettive endemiche e zoonotiche del bestiame possono causare gravi perdite economiche e minacciare la sicurezza alimentare e la salute pubblica. Il progetto REPRODIVAC, finanziato dall’UE, affronterà questo problema riunendo un consorzio di esperti del mondo accademico e industriale con esperienze che spaziano dalla biologia strutturale alla microbiologia, dall’immunologia alle scienze vegetali e veterinarie. Il progetto applicherà un approccio interdisciplinare per sviluppare nuovi vaccini e strumenti diagnostici migliori per le malattie che colpiscono il bestiame, tra cui suini, ovini e caprini. REPRODIVAC si propone di sviluppare un vaccino protettivo contro la sindrome riproduttiva e respiratoria suina, vaccini candidati a subunità per la febbre Q, un vaccino più preciso contro l’aborto enzootico degli ovini, vaccini vivi attenuati contro la Brucella suis e test diagnostici migliori.
Obiettivo
Endemic and zoonotic infectious reproductive diseases of livestock cause major economic losses globally and threaten both food security and public health. REPRODIVAC will develop new and improved vaccines and diagnostic tools required to better control four priority abortifacient diseases: porcine reproductive and respiratory syndrome (PRRS), Q fever, ovine enzootic abortion (OEA), and porcine brucellosis. The consortium spans academia and industry with complementary expertise including structural biology, microbiology, immunology, plant and veterinary sciences. This enables us to address reproductive disorders with an interdisciplinary approach: (1) applying reverse and structural vaccinology to select and design vaccine and diagnostic candidate antigens; (2) exploiting relevant protein expression systems for the production of these antigens; (3) producing rationally attenuated and viral vectored vaccines; and (4) developing a suite of molecular and immunological diagnostic tests, including point-of-care tests (PoC) to discriminate vaccinated from infected animals (DIVA). We will develop a broadly protective PRRSV vaccine, and a serological ELISA that will reliably correlate with PRRSV neutralising antibody titres. We will identify protective subunit vaccine candidates for Q fever and validate a companion serological DIVA test. We will further refine an OEA vaccine for commercialisation and pursue a complementary approach towards a DIVA-compatible next-generation subunit vaccine and serological and molecular DIVA/PoC tests. We will develop live attenuated Brucella suis vaccines and brucellosis diagnostic tests with improved specificity. These new vaccines and diagnostics will be further developed by our industrial partners and made accessible to users. Thereby by using the latest technologies in vaccine and diagnostic development REPRODIVAC will improve animal health and welfare, productivity and sustainability of the livestock sector, as well as human health.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-IA - HORIZON Innovation ActionsCoordinatore
00196 Roma
Italia